glp-1 agonist pregnancy Prenatal exposure to receptor agonists and other second-line antidiabetics may not pose greater risk to infants than insulin GLP-1 weight-loss drugs pose hidden

Some plans exclude weight loss medications altogether

Scrutiny increases in a good way: tighter guardrails on claims, stronger post-market QA, and fewer proprietary blends that promise too much

The impact of GLP-1 usage is not limited to the food and beverage industries

Compared with GLP-1 RAs, more participants receiving tirzepatide 15 mg discontinued treatment due to adverse events (OR 2.29 [95% CI 1.39, 3.75], I 2 0%), whereas no difference was evident for tirzepatide 5 mg and 10 mg (ESM Table 3)

Exenatide, a natural peptide isolated from the saliva of the Gila monster, launched the field in 2005

GLP1 receptor agonists have shown promise in achieving significant weight loss in PWS patients